Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7553.085 | 1.0178 | 1.0317 | 1.1198 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7553.085 | 1.0341 | 1.0608 | 1.1198 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7553.085 | 1.0504 | 1.0897 | 1.1198 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7553.085 | 1.0923 | 1.1641 | 1.1198 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7553.085 | 1.0208 | 1.0371 | 1.1198 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7553.085 | 1.0255 | 1.0455 | 1.1198 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7553.085 | 0.7489 | 0.5448 | 1.1198 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7553.085 | 0.0947 | -0.7562 | 1.1198 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7555.084 | 1.0207 | 1.0242 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7555.084 | 1.0118 | 1.0138 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7555.084 | 1.0448 | 1.0521 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7555.084 | 1.0274 | 1.0319 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7555.084 | 1.0211 | 1.0246 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7555.084 | 1.0139 | 1.0163 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7555.084 | 0.9433 | 0.9328 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7555.084 | 0.9923 | 0.9910 | 1.7052 | |
| ZR75B | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7555.084 | 0.4978 | 0.3285 | 1.7052 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 0.000341 | uM | 10581.136 | 1.0570 | 1.1374 | 0.8342 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 0.00171 | uM | 10581.136 | 0.8838 | 0.7247 | 0.8342 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 0.00853 | uM | 10581.136 | 0.9557 | 0.8942 | 0.8342 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 0.0427 | uM | 10581.136 | 0.9985 | 0.9964 | 0.8342 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 0.213 | uM | 10581.136 | 1.0430 | 1.1034 | 0.8342 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 1.07 | uM | 10581.136 | 0.9093 | 0.7845 | 0.8342 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 5.33 | uM | 10581.136 | 0.9959 | 0.9902 | 0.8342 | |
| BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 26.7 | uM | 10581.136 | 0.7390 | 0.3918 | 0.8342 |